HCC: Achieving Complete Response in a Patient After Liver Transplantation, Metastatic Hepatocellular Carcinoma with Sorafenib Treatment and Radiotherapy Continued with Follow-up_Crimson Publishers
HCC: Achieving Complete Response in a Patient After Liver Transplantation, Metastatic Hepatocellular Carcinoma with Sorafenib Treatment and Radiotherapy Continued with Follow-up by Malgorzata Osmola in Journal of Cancer Research
Crimson Publishers_ Novel Approaches in Cancer Study
Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-associated mortality worldwide, accounting for more than 700000 deaths per year [1]. A large proportion of these patients are not candidates for potentially curative therapy, including liver transplantation or local ablation therapy, as they are diagnosed with advanced or metastatic disease. Sorafenib is an oral tyrosine kinase inhibitor used in cases of unresectable, advanced HCC that significantly improves progression-free and overall survival [2]. Achieving complete response with sorafenib is uncommon; however, if complete radiological response is obtained, the issue of the discontinuation of the treatment remains unsolved. There is also no standard of care for patients after orthotopic liver transplantation (OLTx) due to hepatocellular carcinoma and the choice of immunosuppression.
https://crimsonpublishers.com/nacs/fulltext/NACS.000577.php
For more Open Access Journals in Crimson Publishers please click on: https://crimson-publishers.blogspot.com/2019/10/crimson-publishers-impact-factor.html
For more Articles in Novel Approaches in Cancer Study please click on: https://crimsonpublishers.com/nacs/index.php
Comments
Post a Comment